Monitoring of the estimated glomerular filtration rate (eGFR) in patients with small cell lung cancer during chemotherapy: Equations based on serum creatinine or cystatin C?

Abstract

e19741 Background: Cystatin C (CysC) has been demonstrated as a new marker of glomerular filtration rate. This study compared the differences between eGFR calculated by the Cockcroft&Gault’ (eGFRCG) and CysC-based formula (eGFRCysC) in monitoring renal function in patients with small-call lung cancer (SCLC) during chemotherapy. Methods: Besides the disease-specific parameters, serum creatinine and CysC were detected in 61 patients, and eGFRCG and eGFRCysC after each chemotherapy cycle were calculated and analyzed. Patients also were compared within different eGFR groups. Results: eGFRCysC correlated significantly with serum creatine and eGFRCG respectively (p<0.001). The decreases of eGFRCysC after each treatment cycle were more significant than those decreases of eGFRCG (-3.0634±10.651 vs -0.2274±10.298 ml/min/1.73m2, p=0.001). Single/multi-parameter analysis showed that patients having higher BMI (>23), Scr concentration (>77 μmol/L) and receiving more treatment cycles (>2) were in the increased risk of developing renal impairment with eGFR less than 60 ml/min/1.73 m2 during chemotherapy. Conclusions: The CysC-based formula seems more accurate in predicting eGFR as routine monitoring renal function in patients with SCLC receiving chemotherapy than the CG formula. More attention should be paid to specific patient groups on their renal function during treatment.